CGT Summit 2024 - Heidi Gillenwater, BioNTech, Germany.

BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR T cells manufactured with an automated process ± a CLDN6-encoding CAR T cell-amplifying RNA vaccine (CARVac) by Heidi Gillenwater, BioNTech, Germany.

Despite the success of CAR T cell therapies in hematologic malignancies, the application of these therapies in solid tumors has met several challenges. BNT211 is an investigational CAR T cell therapy targeting Claudin-6 (CLDN6), an oncofetal antigen that is expressed in multiple solid tumor types but is absent in healthy adult tissues.

BNT211-01 (NCT04503278) is a first-in-human, Phase I clinical trial investigating CLDN6 CAR T with or without CLDN6-encoding CAR T-cell amplifying RNA vaccine (CARVac) in patients with relapsed/refractory CLDN6-positive solid tumors. This talk will discuss the rationale of targeting CLDN6, summarize the preclinical studies that support the concept of CARVac-driven expansion of CAR T cells, and share interim clinical data from the BNT211-01 Phase I study.

Talk presented at the Miltenyi Cell and Gene Therapy Summit 2024. Click through to hear more information from your colleagues' experiences and challenges, find relevant upcoming events, or sign up for our newsletter to connect with your community. - Empower cells, empower lives